Rhythm Pharmaceuticals (RYTM) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.73
- Estimate
- -$0.83
- Surprise
- +12.3%
- Revenue (period 2026-06-30)
- $71.3M
- Score at report (before → after)
- 5.7 → 5.7/10
Revenue source: xbrl.
How the report landed
Rhythm Pharmaceuticals (RYTM) reported a narrower loss than forecast — diluted EPS of -$0.73 against the -$0.83 estimate (a 12.3% beat on a still-unprofitable quarter). TrendMatrix's engine moved from Buy (Wait) (5.7/10) to Sell at 5.7/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates RYTM Sell at 5.2/10.
3 of the last 4 quarters beat the estimate; this quarter's +12.3% surprise compares with a +2.7% four-quarter average. Next scheduled report: 2026-11-03.
What argues against it
- Concentration risk — Product: setmelanotide
- Quality below floor (3.6 < 4.0)
- Value-trap signals (2/5): Margin compression (op margin -62.9%), Material insider selling (13 sells, 4.25% of cap)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $103.36
- Price target
- $126.17
- Stop
- $99.93
- Upside to target
- +22.1%
- Reward-to-risk
- 2.7:1
Risk check: RSI 26 — a level conventionally read as oversold.
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
RYTM at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $7.22B
- P/E (fwd)
- -170.8
- 52-week range
- $74.50–$122.20
- Off 52-week high
- 15.4%
- RSI (14)
- 26
- Volume vs avg
- 0.07×
- Score today
- 5.2/10